Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q9BWV3

UPID:
CDAC1_HUMAN

ALTERNATIVE NAMES:
Cytidine deaminase; Testis development protein NYD-SP15

ALTERNATIVE UPACC:
Q9BWV3; Q49A08; Q4G119; Q5TAW9; Q7Z764; Q9NT36

BACKGROUND:
The protein known as Cytidine and dCMP deaminase domain-containing protein 1, with alternative names Cytidine deaminase and Testis development protein NYD-SP15, is integral to the deamination process of cytidine and deoxycytidine, converting them into uridine and deoxyuridine. This biochemical reaction is vital for the maintenance and integrity of nucleic acids in cells. Additionally, its significant role in testicular development and spermatogenesis underscores its importance in fertility and reproductive health.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Cytidine and dCMP deaminase domain-containing protein 1 offers a promising avenue for developing novel therapeutic approaches. Given its critical roles in nucleotide metabolism and reproductive biology, targeting this protein could lead to breakthroughs in treating metabolic and reproductive disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.